Last reviewed · How we verify

Duranest — Competitive Intelligence Brief

Duranest (ETIDOCAINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: etidocaine. Area: Neuroscience.

marketed etidocaine Potassium channel subfamily K member 3, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 4 subunit alpha Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Duranest (ETIDOCAINE).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Duranest TARGET ETIDOCAINE marketed etidocaine Potassium channel subfamily K member 3, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 4 subunit alpha 1976-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (etidocaine class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Duranest — Competitive Intelligence Brief. https://druglandscape.com/ci/etidocaine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: